血清富半胱氨酸61、乙二醛酶Ⅰ、微小RNA-155对子宫内膜癌的诊断价值

Diagnostic value of cysteine rich 61,glyoxalaseⅠand microRNA-155 in endometrial carcinoma

目的探讨血清富半胱氨酸61(Cyr61)、乙二醛酶Ⅰ(GLO-1)、微小RNA-155(miR-155)对子宫内膜癌的诊断价值。方法选取鲁西南医院2017年6月至2020年3月诊治的85例子宫内膜癌患者作为观察组,其中复发15例,未复发70例;另选取同期收治的子宫良性病变患者85例作为对照组。比较两组血清Cyr61、GLO-1、miR-155水平,分析血清Cyr61、GLO-1、miR-155水平与临床病理特征的相关性,绘制受试者工作特征(ROC)曲线,评价血清Cyr61、GLO-1、miR-155水平对子宫内膜癌的诊断价值,分析血清Cyr61、GLO-1、miR-155水平与子宫内膜癌复发的关系。结果观察组血清Cyr61、GLO-1、miR-155水平均高于对照组[(294.74 ± 78.41)μg/L比(156.82 ± 50.62)μg/L、(96.27 ± 19.85)pmol/L比(79.83 ± 15.69) pmol/L、6.82 ± 2.27比2.57 ± 0.78],差异有统计学意义(P<0.05)。子宫内膜癌患者血清Cyr61、GLO-1、miR-155水平与临床分期、肌层浸润、淋巴结转移呈正相关(P<0.05)。血清Cyr61、GLO-1、miR-155联合诊断子宫内膜癌的曲线下面积为0.906。子宫内膜癌复发患者血清Cyr61、GLO-1、miR-155水平高于未复发患者[(358.21 ± 89.63)μg/L比(281.14 ± 75.29) μg/L、(109.89 ± 20.14) pmol/L比(93.35 ± 16.37) pmol/L、8.04 ± 2.51比6.56 ± 2.17],差异有统计学意义(P<0.05)。血清Cyr61、GLO-1、miR-155水平均为子宫内膜癌患者复发的危险因素(P<0.05)。结论子宫内膜癌患者血清Cyr61、GLO-1、miR-155水平明显升高,且与临床分期、浸润程度、淋巴结转移及复发有关,检测其水平可及时诊断子宫内膜癌,预测复发,从而指导临床治疗。

Objective To investigate the diagnostic value of cysteine rich 61(Cyr61),glyoxalaseⅠ(GLO-1)and microRNA-155(miR-155)in endometrial carcinoma.Methods Eighty-five patients with endometrial cancer treated in Lu Southwest Hospital from June 2017 to March 2020 were selected as the observation group,including 15 cases of recurrence and 70 cases of non-recurrence.In addition,85 patients with benign uterine lesions were selected as the control group.The levels of serum Cyr61,GLO-1 and miR-155 were compared between the two groups,the correlation between the levels of serum Cyr61,GLO-1 and miR-155 and clinicopathological features were analyzed,the receiver operating characteristic(ROC)curve was drawn,the diagnostic value of the levels of serum Cyr61,GLO-1 and miR-155 in endometrial cancer were evaluated,and the relationship between the levels of serum Cyr61,GLO-1 and miR-155 and the recurrence of endometrial cancer were analyzed.Results The levels of serum Cyr61,GLO-1 and miR-155 in the observation group were higher than those in the control group:(294.74±78.41)μg/L vs.(156.82±50.62)μg/L,(96.27±19.85)pmol/L vs.(79.83±15.69)pmol/L,6.82±2.27 vs.2.57±0.78,the differences were statistically significant(P<0.05).The levels of serum Cyr61,GLO-1 and miR-155 in patients with endometrial cancer were positively correlated with clinical stage,myometrial invasion and lymph node metastasis(P<0.05).The area under the curve(AUC)of serum Cyr61,GLO-1 and miR-155 in the combined diagnosis of endometrial cancer was 0.906.The levels of serum Cyr61,GLO-1 and miR-155 in recurrence patients were higher than those non-recurrence patients:(358.21±89.63)μg/L vs.(281.14±75.29)μg/L,(109.89±20.14)pmol/L vs.(93.35±16.37)pmol/L,8.04±2.51 vs.6.56±2.17,the differences were statistically significant(P<0.05).The levels of serum Cyr61,GLO-1 and miR-155 were the risk factors of recurrence in patients with endometrial cancer(P<0.05).Conclusions The levels of serum Cyr61,GLO-1 and miR-155 in patients with endometrial cancer are significantly increased,which are related to clinical stage,degree of invasion,lymph node metastasis and recurrence.Detecting their levels can be used to diagnose endometrial cancer and predict recurrence,so as to guide clinical treatment.